Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Yun, Tak ^a   Han, Ji Youn ^a   Lee, Jin S ^a   Choi, Hyun L ^a   Kim, Hyae Y ^a   Nam, Byung Ho ^a   Kim, Heung T ^a  

^a National Cancer Center   (South Korea)

Author keywords

Capecitabine; Paclitaxel; Squamous cell carcinoma of the esophagus

Indexed keywords

CAPECITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL;

EID: 80052253286     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-385     Document Type: Article

References (29)

1. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999, 26(5 Suppl 15):12-20.
2. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998, 16(5):1826-1834.
3. Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 1996, 78(10):2070-2077. 10.1002/(SICI)1097-0142(19961115)78:10<2070::AID-CNCR6>3.0.CO;2-S, 8918399.
4. Ohwada S, Nakamura S, Izumi M, Kawashima Y, Ogawa T, Kobayashi I, Hosomura Y, Joshita T, Lino Y, Morishita Y. Neoadjuvant chemotherapy with etoposide, leucovorin, 5-fluorouracil and cisplatin for advanced esophageal squamous cell carcinoma. Jpn J Clin Oncol 1995, 25(3):79-85.
5. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001, 31(9):419-423. 10.1093/jjco/hye090, 11689594.
6. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999, 17(10):3270-3275.
7. Nakadate M, Yamazaki K, Konishi J, Kinoshita I, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, et al. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Anticancer Res 2006, 26(5B):3767-3772.
8. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006, 17(1):104-109.
9. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45(4):291-297. 10.1007/s002800050043, 10755317.
10. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998, 4(4):1013-1019.
11. Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, Lee HG, Lee SY, Shin EH, Lee JS. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer 2003, 98(9):1918-1924. 10.1002/cncr.11738, 14584075.
12. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823. 10.1200/JCO.2002.09.002, 12065558.
13. Park YH, Ryoo BY, Choi SJ, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004, 90(7):1329-1333. 10.1038/sj.bjc.6601724, 2409690, 15054450.
14. Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res 2007, 27(4C):2845-2848.
15. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004, 18(14 Suppl 14):22-25.
16. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2007, 67(2):397-404. 10.1016/j.ijrobp.2006.08.062, 17097833.
17. Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol 2006, 13(2):214-220. 10.1245/ASO.2006.01.001, 16418887.
18. van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 2007, 96(9):1348-1352. 2360191, 17437008.
19. Qin TJ, An GL, Zhao XH, Tian F, Li XH, Lian JW, Pan BR, Gu SZ. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol 2009, 15(7):871-876. 10.3748/wjg.15.871, 2653389, 19230050.
20. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008, 62(1):77-84. 10.1007/s00280-007-0577-6, 17762932.
21. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 2005, 92(12):2129-2133. 10.1038/sj.bjc.6602645, 2361804, 15942631.
22. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010, 28(24):3824-3829. 10.1200/JCO.2010.29.1807, 20625131.
23. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010, 102(3):475-481. 10.1038/sj.bjc.6605522, 2822950, 20068567.
24. Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, Xi W, Li H, Jin Y. A Phase II Study of Paclitaxel and Nedaplatin as First-line Chemotherapy in Patients with Advanced Esophageal Cancer. Jpn J Clin Oncol 2009,
25. Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol 2009, 64(2):327-333. 10.1007/s00280-008-0874-8, 19048253.
26. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009, 20(10):1667-1673. 10.1093/annonc/mdp069, 19549707.
27. Petrasch S, Welt A, Reinacher A, Graeven U, Konig M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998, 78(4):511-514. 10.1038/bjc.1998.524, 2063082, 9716036.
28. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002, 86(5):669-673. 10.1038/sj.bjc.6600166, 2375296, 11875723.
29. Zhang X, Shen L, Li J, Li Y, Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol 2008, 31(1):29-33. 10.1097/COC.0b013e3181131ca9, 18376224.